Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day-1) in the treatment of cutaneous or lymphocutaneous sporotrichosis

Mycoses

Volumn 47, Issue 1-2, 2004, Pages 62-68

  Chapman, S W ^a   Pappas, P ^b   Kauffmann, C ^c   Smith, E B ^d   Dietze, R ^e   Tiraboschi Foss, N ^f   Restrepo, A ^g   Bustamante, A B ^h   Opper, C ^b,i   Emady Azar, S ⁱ   Bakshi, R ⁱ  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF NEW MEXICO   (United States)

^e Univ Ferderal do Espirito Santo   (Brazil)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

^g UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^h INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antimycotic chemotherapy; Efficacy; Lymphocutaneous infection; Sporotrichosis; Terbinafine

Indexed keywords

TERBINAFINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL TOXICITY; HEARING DISORDER; HUMAN; LIVER TOXICITY; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEUROTOXICITY; NUTRITIONAL DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN INFECTION; SPOROTHRIX SCHENCKII; SPOROTRICHOSIS; TASTE DISORDER; VESTIBULAR DISORDER; VISUAL DISORDER;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LYMPHATIC DISEASES; MALE; MIDDLE AGED; NAPHTHALENES; RECURRENCE; SPOROTHRIX; SPOROTRICHOSIS; TREATMENT OUTCOME;

SPOROTHRIX; SPOROTHRIX SCHENCKII;

EID: 12144290885     PISSN: 09337407     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1439-0507.2003.00953.x     Document Type: Article

References (27)

1. Kwon-Chung KJ, Bennet JE. Sporotrichosis. In: Kwon-Chung KJ, Bennett JE (eds), Medical Mycology. Philadelphia: Lea & Febiger, 1992: 707-29.
2. Hajjeh R, McDonnell S, Reef S et al. Outbreaks of sporotrichosis among tree nursery workers. J Infect Dis 1997; 176: 499-504.
3. Chapman SW, Daniel CR. Cutaneous manifestations of fungal infection. Infect Dis Clin N Am 1994; 95: 879-910.
4. Winn RE. Sporotrichosis. Infect Dis Clin N Am 1988; 2: 899-911.
5. Rex JH, Bennet JE. Administration of potassium iodide to normal volunteers does not increase killing of Sporothrix schenckii by their neutrophils or monocytes. J Med Vet Mycol 1990; 28: 185-9.
6. Kauffman CA. Old and new therapies for sporotrichosis. Clin Infect Dis 1995; 21: 981-5.
7. Kauffman CA, Hajjeh R, Chapman SW. Practice guidelines for the management of patients with sporotrichosis. For the Mycoses Study Group. Infectious Diseases Society of America. Clin Infect Dis 2000; 30: 684-7.
8. Evans EGV, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in the treatment of toenail onychomycosis. BMJ 1999; 318: 1031-5.
9. Sigurgeirsson B, Olafsson JH, Steinsson JB et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 2002; 138: 353-7.
10. Ryder NS, Leitner I. In vitro activity of terbinafine (Lamisil): an update. J Dermatol Treat 1998; 9: S23-8.
11. Shadomy S, Espinel-Ingroff A, Gebhart RJ. In-vitro studies with SF 86-327, a new orally active allylamine derivative. Sabouradia 1985; 23: 125-32.
12. Hull PR, Vismer HF. Treatment of cutaneous sporotrichosis with terbinafine. Br J Dermatol 1992; 126(Suppl. 39): 51-55.
13. Forsana CV, Carrozzo V, Forte I, Peserico A. Cutaneous lymphangitic sporotrichosis treated with terbinafine. Acta Dermatol Venereol 1994; 3: 161-3.
14. Kudoh K, Kamei E, Terunama A et al. Successful treatment of cutaneous sporotrichosis with terbinafine. J Dermatol Treat 1996; 7: 33-35.
15. Jacyk WK, Ayerst KF, Röscher M. Sporotrichosis. Review of sixty-five cases from South Africa. Mikol Lek 2000; 7: 189-96.
16. Morishita N, Yamazaki K, Ninomiya J et al. A case of lymphocutaneous sporotrichosis. Nippon Ishinkin Gakkai Zasshi 2001; 42: 149-54.
17. Morris-Jones R, Sarkany R, Hay J. Lymphocutaneous sporotrichosis. Br J Dermatol 2001; 145: 38-39.
18. Petranyi G, Meingassner JG, Mieth H. Antifungal activity of allylamine derivative terbinafine in vitro. Antimicrob Agents Chemother 1987; 31: 1365-8.
19. Hay RJ. Therapeutic potential of terbinafine in subcutaneous and systemic mycoses. Br J Dermatol 1999; 141: 36-40.
20. Perez A. Terbinafine: broad new spectrum of indications in several subcutaneous and systemic and parasitic diseases. Mycoses 1999; 42(Suppl. 2): 111-4.
21. Lesher JL, Fitch MH, Dunlap DB. Subclinical hypothyroidism during potassium iodide therapy for lymphocutaneous sporotrichosis. Cutis 1994; 53: 128-30.
22. Scully RE, Mark EJ, McNeely WF, McNeely BU. Case records of the Massachusetts General Hospital: case 28, 1994. N Engl J Med 1994; 331: 181-7.
23. Conti Diaz IA, Civilia E, Gezule E et al. Treatment of human cutaneous sporotrichosis with itraconazole. Mycoses 1992; 35: 153-6.
24. Sharkey-Mathis PK, Kauffman CA, Graybill JR et al. Treatment of sporotrichosis with itraconazole. Am J Med 1993; 95: 279-85.
25. Karakayali G, Lenk N, Ali N, Gungor E, Artuz F. Itraconazole therapy for lymphocutaneous sporotrichosis: a case report and review of the literature. Cutis 1998; 61: 106-7.
26. Faergemann J, Zehender H, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 1994; 19: 121-6.
27. Adel-Rhaman SM, Nahata MC. Oral terbinafine: a new antifungal agent. Ann Pharmacother 1997; 31: 445-56.